DoW Toxic Exposures Translational Research Award

The Toxic Exposures Research Program Translational Research Award is offered by the Defense Health Agency through the Congressionally Directed Medical Research Programs. This federal funding opportunity is designed to advance research that addresses the health impacts of military-related toxic exposures. Established by Congress in 2022, the Toxic Exposures Research Program seeks to improve the health and quality of life of Service Members, Veterans, their families, and the broader public by funding research that enhances prevention, diagnosis, and treatment of conditions linked to toxic exposures. This award specifically focuses on translational research, which bridges basic scientific discovery and clinical application. The primary purpose of the Translational Research Award is to accelerate the movement of promising scientific findings into practical clinical applications. These applications may include healthcare products, interventions, diagnostic tools, technologies, or clinical practice guidelines. The program emphasizes integration between laboratory-based research and clinical observations, requiring applicants to demonstrate how their work facilitates a reciprocal exchange of knowledge between these domains. Projects must clearly articulate the current state of the field, the anticipated advancements resulting from the research, and the next steps toward implementation in clinical settings. Funding for this opportunity is limited, with approximately six million dollars expected to be distributed across about four awards. Each award may request up to one and a half million dollars in total costs over a maximum performance period of three years. Funds may be used for a range of research-related expenses, including personnel, materials, and limited travel for collaboration and dissemination of findings. However, clinical trials are not permitted under this mechanism, and certain research areas, such as classified research or studies involving specific prohibited agents, are excluded. Cost sharing is not required, making the program more accessible to a wide range of applicants. Eligibility for this award is broad and inclusive. Both domestic and international organizations may apply, including academic institutions, nonprofit organizations, for-profit entities, and government agencies. Principal Investigators must be independent researchers affiliated with eligible organizations, and individuals in training positions are not eligible to serve as primary investigators. The program also offers a Partnering Principal Investigator Option, which allows two investigators to collaborate on a project, each receiving a separate award. This structure is intended to encourage interdisciplinary collaboration and enhance the translational impact of the research. The application process consists of two stages. First, applicants must submit a pre-application through the Electronic Biomedical Research Application Portal. This includes a concise narrative outlining the research concept, alignment with program goals, and anticipated impact. Selected applicants will then be invited to submit a full application, which requires detailed documentation such as a project narrative, technical and lay abstracts, a statement of work, and various supporting materials. Full applications are submitted through Grants.gov or eBRAP, depending on the applicant’s affiliation, and must adhere to strict formatting and content requirements. Applications are evaluated through a two-tier review process. The first stage is peer review, where experts assess the scientific merit, feasibility, translational potential, and impact of the proposed research. The second stage is programmatic review, which considers how well the application aligns with program priorities and contributes to a balanced research portfolio. Key evaluation criteria include the strength of the research strategy, the quality of preliminary data, the potential for clinical translation, and the relevance to military health needs. The timeline for this funding opportunity includes a pre-application deadline of August 19, 2026, followed by an invitation-only full application deadline of November 19, 2026. Peer review is expected to occur in January 2027, with programmatic review in March 2027. Awards are anticipated to be made by September 30, 2027. Applicants must ensure that all required registrations, including SAM.gov and Grants.gov, are active prior to submission. For assistance, applicants may contact the eBRAP Help Desk or the Grants.gov Support Center for technical support throughout the application process.

Emphasize strong preliminary data and clear translational pathway; demonstrate clinical relevance to military populations; align explicitly with program goals and topic areas; clearly articulate short and long term impact